Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients.

Date publication

juillet 2019

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GUERCI-BRESLER Agnès , Dr LAROSA Fabrice

Tous les auteurs :
Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Réa D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31292142

Résumé

TKI discontinuation is an emerging goal in CML management and several studies demonstrated the feasibility of stopping safely imatinib. A sustained DMR on long-term TKI is critical prior to attempting treatment-free remission (TFR). Results reported recently, failed to identify robust and reproducible predictive factors for the selection of the best candidates for successful TFR.

Référence

Clin. Cancer Res.. 2019 Jul 10;: